Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Mol Cancer Ther. 2018 Feb 26;17(5):1079–1089. doi: 10.1158/1535-7163.MCT-17-0137

Figure 5. EGFR and mTOR inhibitors decrease proliferation of GCT cells in vitro.

Figure 5

A, Immunoblots showing response of mTOR phosphorylation to a range of rapamycin doses in NCCIT and NTERA2 cells exposed to drug for 12 hours in serum-starved conditions. See Supplementary Figures 2 and 3 for complete blots. B, Immunoblots showing response of Erk1/2 phosphorylation to a range of erlotinib doses in NCCIT cells exposed to drug for 12 hours in serum-starved conditions. C, D, Cell proliferation of (C) NCCIT and (D) NTERA-2 cells in the presence of erlotinib, rapamycin, or the combination.